Advisory Services Network’s Esperion Therapeutics ESPR Stock Holding History

Advisory Services Network’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,050	Closed	-$5.62K	–	2922
2026 Q1	$5.62K	Buy	+2,050	New	+$6.49K	﹤0.01%	3799
2025 Q4	–	Sell	-2,050	Closed	-$5.43K	–	2554
2025 Q3	$5.43K	Buy	+2,050	New	+$3.96K	﹤0.01%	3504
2024 Q1	–	Sell	-62	Closed	-$185	–	2109
2023 Q4	$185	Buy	+62	New	+$80	﹤0.01%	3740
2023 Q2	–	Sell	-1,112	Closed	-$1.77K	–	2107
2023 Q1	$1.77K	Buy	1,112 +1,000	+893%	+$5.16K	﹤0.01%	3465
2022 Q4	$698	Buy	+112	New	+$801	﹤0.01%	3678
2020 Q4	–	Sell	-51	Closed	-$2K	–	3407
2020 Q3	$2K	Buy	+51	New	+$2.02K	﹤0.01%	3098
2019 Q4	–	Sell	-500	Closed	-$23K	–	3128
2019 Q3	$23K	Hold	500	–	–	﹤0.01%	1744
2019 Q2	$23K	Hold	500	–	–	﹤0.01%	1742
2019 Q1	$20K	Hold	500	–	–	﹤0.01%	1614
2018 Q4	$23K	Hold	500	–	–	﹤0.01%	1433
2018 Q3	$22K	Buy	+500	New	+$23K	﹤0.01%	1535

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Advisory Services Network's ESPR Position: Q2 2026 in Review

Advisory Services Network sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 2,050 shares — an estimated $5.62K sold.

Advisory Services Network first reported a position in ESPR in Q3 2018 and held it in 11 quarters. The position peaked at $23K in Q3 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Advisory Services Network reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 2,050 Esperion Therapeutics shares in Q2 2026, an estimated $5.62K.
Advisory Services Network first reported a position in Esperion Therapeutics in Q3 2018 and held it in 11 quarters.
Advisory Services Network's Esperion Therapeutics position peaked at $23K in Q3 2019.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.